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The European Federation for Exploratory Medicines Development (EUFEMED) organized
a meeting in Leuven, Belgium entitled ‘The new FIH EMA guideline: Disruptive or
constructive?’ to provide a forum for stakeholders to discuss the guideline’s operational
impact. The revised EMA Guideline on strategies to identify and mitigate risks for
first-in-human (FIH) and early clinical trials with investigational products was published
on 20 July 2017. The revision gave guidance on sentinel dosing/staggering of
subjects within a multiple-ascending dose (MAD) clinical trial, permissible maximum
exposure/investigation of supra-therapeutic doses and dose escalations above the
no-observed adverse effect level. As the guidelines came into operation on 1 February,
2018 it was assumed that by the date of the meeting many early phase stakeholders
had gathered sufficient first-hand experience of working within the guideline to discuss
their thoughts on its impact. The concluding part of the meeting focused on the possible
differences between European countries in handling the revised FIH guideline and ways
of achieving harmonization. Information on current industry practice was gathered by
online polling during the meeting, where perception of the revised guideline as either
‘disruptive’ or ‘constructive’ was explored at the start and at the end of the Forum
along with recommendations on reducing future regulatory discordance. It was generally
agreed that the necessary changes encompassed by new guidelines included both
constructive and disruptive aspects. The final vote on whether the new FIH guideline
is disruptive or constructive was taken by 69 delegates: 51% stated that it was both
constructive and disruptive, 48% decided on constructive, none on disruptive and 1%
were still undecided. It was generally accepted that stakeholders need to continue in
a process of stakeholder engagement and discussion, particularly on critical safety
issues. Such an approach allows partners to adopt a proactive approach to sharing
best practice. For example, attendees agreed that a ‘Question and Answer’ document
harmonized between the European agencies is required for the sentinel approach and
for the selection of supratherapeutic doses.
Keywords: early phase clinical drug development, revised first-in-human guideline, conference report, EMA
(European Medicines Agency), guidelines, EUFEMED, discussion
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INTRODUCTION
The European Federation for Exploratory Medicines
Development (EUFEMED1) is a not-for-profit association that
aims to improve the early phase clinical drug development
process in Europe (Van Bortel et al., 2018). On the 19
September 2018, EUFEMED organized a meeting in Leuven,
Belgium entitled ‘The new FIH EMA guideline: Disruptive
or constructive?’ to provide a forum for stakeholders to
discuss the guideline’s operational impact. The revised
EMA Guideline on strategies to identify and mitigate risks
for First-in-Human (FIH) and early clinical trials with
investigational products was published on 20 July 2017
(European Medicines Agency Science Medicines Health,
2017). The revision gave guidance on sentinel dosing
(where one person in a first cohort of participants receives
a single dose of investigational product in advance of the full
study cohort) and the staggering of subjects (that includes
a specified follow-up interval between administration of
the product to a subject, or small group of subjects, and
administration to the next subject or group of subjects)
within a multiple-ascending dose (MAD) clinical trial. The
guideline also considers permissible maximum exposures and
the use of supra-therapeutic doses as well as dose escalations
that extend beyond the predicted no-observed adverse effect
level. As the guidelines came into operation on 1 February,
2018 it was assumed that by the date of the meeting many
early phase stakeholders had gathered sufficient first-hand
experience of working within the guideline to discuss their
thoughts on its impact.
The event welcomed over 100 attendees. The aim was
for the audience to drive the program through the use of
active directed polling employing the sli.do online tool2. The
audience were initially asked to provide feedback on their
areas of specific expertise: 51% worked in contract research
organizations or as consultants; 38% were sponsors (from
pharmaceutical companies) or investigators; 11% represented
competent authorities or ethics committees. Participants were
also asked at the outset whether they felt that the revised
FIH guideline was disruptive or constructive: 35% of the
responders indicated that the guidelines were constructive, 1%
disruptive, 47% both constructive and disruptive and 16%
felt that they didn’t know enough to comment. Electronic
balloting of attendees continued throughout the meeting, with
the organizers seeking their opinion, understanding and insights
regarding the guidelines as well as any difficulties they may
have experienced when they first started working with the
updated recommendations.
Prior to the meeting, the membership of EUFEMED and
other stakeholders involved in early medicines development
were canvassed for their opinion on various aspects of the
new EMA guideline. The assessment was conducted in the
form of two online polls, one was conducted by the French
Club Phase I association in September 2017 (Sourgens and
1www.eufemed.eu
2www.sli.do
Donazzolo, 2018b) and the other by EUFEMED in March
2018. The polls were similar but not identical in format
(Sourgens and Donazzolo, 2018a).
French regulatory authorities introduced new regulatory
guidelines in March 2016 following the BIA 10-2474 incident
that occurred in January 2016, where a participant in a Phase
I trial died. Provisions made in terms of stopping rules were
included in the revised EMA FIH guideline. The impact of
the change in regulations was addressed in an online survey
of early development stakeholders across France in September
2017 (Sourgens and Donazzolo, 2018b). Of those responding,
39 considered themselves to be active and experienced in early
medicines development: of these, fewer than 5% felt that the
revised guideline could be considered ‘very clear’; approximately
90% felt little need to make anything more than minor changes to
methods used for the identification of starting doses; more than
80% reported no or minor changes in the definition of stopping
rules and the sentinel approach. Areas of most concern included:
1. Difference of interpretation of the revised guideline
between countries;
2. Identification/selection of animal species relevant for
pharmacology AND toxicity AND metabolism;
3. Clarification of investigations needed regarding
metabolites in toxicology and safety pharmacology
studies;
4. Top dose: evaluation of supra-therapeutic doses;
5. Defining meaningful target pharmacodynamic changes in
healthy subjects;
6. Limits to maximum exposure;
7. Clear requirements for determining maximum dose:
exclusivity of pharmacodynamic and/or pharmacokinetic
data; and
8. Increasing doses in early phase trials beyond the animal no-
observed-adverse-effect level (NOAEL).
The impact of the implementation of the revised guideline on
early clinical development in the European Union was rated as
neutral to positive by more than 80% of the French responders.
The survey of the EUFEMED membership was submitted
to approximately 1,000 candidates, 125 of who provided a
response (Sourgens and Donazzolo, 2018a). Overall, only minor
differences emerged between the findings of the French and the
European surveys. Most responders were based in Western parts
of Europe and represented sponsors and investigators or were
employed by contract research organizations. The majority (88%)
indicated that they were well experienced in FIH trials: 72%
reporting having conducted more than 10 FIH trials over the last
10 years, including clinical trials with first-in-class compounds,
small molecules, biologics and well-known medicines. It was
therefore concluded that any findings from the survey would
represent the opinions and experiences of highly motivated
and educated stakeholders in early clinical development. Of the
survey responders, 31% felt that the revised guideline was ‘very
clear’; 74% acknowledged little more than minor changes in
the selection of the starting dose and 68% reported little or no
change to the definition of stopping rules (for individuals and
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cohorts). However, more than 90% felt that the totality of revised
instructions represented a marked change to current practice.
Aspects of the guidelines that elicited most interest involved
sentinel dosing, definition of maximum exposure, decisions
on dose escalation steps and understanding of non-clinical
requirements. Overall, 80% of responders indicated that the
impact of the implementation of the revised guideline on early
clinical development in the EU was neutral to positive.
VIEWPOINTS AND EXPERIENCE OF
EUROPEAN REGULATORY AGENCIES
Representatives from six European regulatory agencies and the
European Medicines Agency (EMA) provided the audience with
their perspectives of the implementation of the revised guideline.
Their briefing in preparation for the meeting comprised the
following requests for elucidation on their current position:
1. Percentage of FIH clinical trials requiring refusal because of
non-adherence to the revised guideline, ethical constraints;
2. Percentage of FIH trials NOT requiring any comments,
approvable and full in line with the revised FIH guidance;
3. Do you experience other concerns not addressed in
the survey?
European Medicines Agency
Stefano Ponzano from the Clinical Pharmacology and
Non-clinical Support Office of the EMA commented on
recent experience of questions submitted to the agency for
scientific advice on FIH clinical trials (Stefano, 2018). He noted
that the number of requests for advice from the agency has been
decreasing since the publishing of the guideline, though this
observation was based on the limited data. Reviewing the last
16 requests submitted to the EMA since 2017, where questions
were put to the Committee for Medicinal Products for Human
Use (CHMP) about FIH trials, the most frequently submitted
questions related to the design of FIH clinical trials (12 of 27
questions). The main topics covered target populations, endpoint
selection, dose level identification, study stopping criteria and
safety monitoring as well as which criteria are required to move
from a FIH clinical trial in healthy volunteers to a first in patients
trial under integrated protocols.
Some examples of recommendations provided by the
CHMP through the scientific advice procedures, included
the necessity for sponsors to provide additional data from
in vitro non-clinical studies to better define proof of concept
and to underline the relevance of the animal species used
in the non-clinical studies with regards to preparing for
clinical trials. Based on the level of uncertainty, sponsors
were advised to consider not only the NOAEL but also
the minimal anticipated biological effect level [MABEL] and
the pharmacologically active dose [PAD] when calculating
starting doses. The CHMP recommend providing justification
when sponsors want to investigate doses beyond the predicted
pharmacodynamic range. In particular, the agency request a clear
rationale for proposed doses beyond the envisaged maximum
dose as well as proposing less aggressive dose escalation strategies
depending on the level of uncertainty of the investigational
medicinal product.
In concluding his presentation, Stefano Ponzano highlighted
that his assessment was based on a small sample making it
difficult to assess the extent to which the revised guideline has
impacted on the type or number of requests being submitted to
the agency. He did, however, express the importance of achieving
harmonization of FIH decisions provided by the various
European agencies. Dr. Ponzano recalled several initiatives that
the EMA are currently involved with to achieve closer working
standards, such as a non-clinical training curriculum that is
currently being developed by the EU Network Training Centre.
The curriculum will include webinars for non-clinical assessors
related to the FIH guideline. The Clinical Trial Facilitation Group
(CTFG) in collaboration with the EU NTC organized a workshop
in March 2017 for non-clinical and clinical assessors on the
revision of the FIH guideline. The Clinical Trial Regulation,
which entered into force on 16 June 2014, identifies the EMA
as being responsible for developing and maintaining the clinical
trial portal and database in collaboration with the Member States
and the European Commission. Stakeholders will have access to
the submission of clinical trial applications and authorizations
within the EU once the single EU portal becomes active. It
is envisaged that this will be an important tool in identifying
possible issues linked to the implementation of the new guideline.
A close interaction between the EMA and the various competent
authorities remains key to achieving harmonization. A general
but important remark made was that the guideline is driven by
science, it is a tool to help develop a safe and correct clinical trial.
It remains imperative to provide thorough scientific information
in the reports and submission documents, ensuring the safety
of the subjects.
Medicines and Healthcare Products
Regulatory Agency, United Kingdom
Kirsty Wydenbach, Senior Medical Assessor and Deputy Unit
Manager CTU at the UK Medicines & Healthcare products
Regulatory Agency (MHRA) reported on the numbers of FIH
clinical trials conducted in the United Kingdom (Wydenbach,
2019). Records indicate that 20 – 25% of all FIH clinical trials in
the EU have some UK involvement. Reviewing the available data,
it seems that there has been no change in the number of ‘Grounds
for Non-Acceptance’s’ (GNAs) issued by the agency since the
implementation of the revised guidance and no rejections due
to non-compliance with the revised guideline. Overall, the rate
of Phase I rejections issued by the MHRA is in line with all
other phase trials.
Surprisingly, most rejections resulted from sponsors not
responding at all to GNAs (five of eight). Reasons for the
provision of the GNAs included: absence of communication
plans for multi-site trials; failure to provide a maximum dose or
maximum number of cohorts; unclear individual stopping rules
or rules for stopping specific parts of the trials or the whole
trial; poor consideration of the potential for drug interactions
in protocols that include combination therapy or concomitant
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medications (ignoring Summary of Product Characteristics risks
for marketed products); contraception not aligned with CTFG
guidance and inadequate pregnancy testing; proposed healthy
volunteers doses far above predicted therapeutic range without
any clear justification being provided; no clear characterization
of analytical assays used in non-clinical pharmacokinetic and
toxicokinetics; lack of quality data. No trend in the issuing
of GNAs was apparent when assessed by product type (small
molecular entities or biologics).
None of the examples provided were considered by the MHRA
to be particularly specific to FIH trials. These findings reflected
those reported in the ‘Common issues identified during clinical
trial applications’ recently published on the MHRA website
(Medicines and Healthcare Products Regulatory Agency, 2018).
In terms of issues such as dose ranges in healthy volunteers that
extend beyond the therapeutic range, Dr. Wydenbach noted that
the MHRA requires sponsors to provide justification for their
dosing strategy and provide sufficient data to thoroughly assess
their position. She also noted that protocols that include adaptive
elements are welcomed by the MHRA, provided they are clearly
defined upfront. Inclusion of adaptive elements at a later date
may be accepted as long as any supporting rationale is based on
emerging data. Sentinel dosing is not seen universally across trials
and it is not a required aspect for trials in United Kingdom; the
MHRA feel that it is acceptable not to apply a sentinel dosing
strategy when a suitable justification is provided.
In concluding, Dr. Wydenbach stated that the implementation
of the revised FIH guideline has had no noticeable impact on
submissions to or approvals issued by the MHRA. Expectations
remain unchanged for the future. According to her experience,
the biggest barrier to innovation is not seeking advice from a
regulator early enough or at all.
Bundesinstitut für Arzneimittel und
Medizinprodukte, Germany
Sarah Heil, Clinical Assessor at Bundesinstitut für Arzneimittel
und Medizinprodukte (BfArM, Germany), emphasized that the
revised FIH guideline underlines how safety should not be
compromised in the interests of speed of acquiring data or
for logistical reasons. Thus, risk mitigation activities should be
proportionate to the degree of uncertainty and the potential
risks identified.
Maximum Exposure
Sarah Heil noted that maximum exposure must take non-clinical
data into account and must not exceed the NOAEL recorded in
the most sensitive species. Healthy subjects should not be exposed
to doses exceeding the anticipated therapeutic dose without a
clear rationale (ATD). The maximum tolerated dose (MTD)
needs to be well defined in patients, whereas it is regarded as
unethical to assess the MTD in healthy subjects.
Pharmacokinetic-Pharmacodynamic Data for Dose
Escalation
The information required in the protocol and the Investigator’s
Brochure should include sufficient data on:
(i) Primary and secondary pharmacodynamics;
(ii) Mode of action;
(iii) Interaction with ‘off-targets’ (e.g., secondary
pharmacodynamics);
(iv) Pharmacokinetics and toxicokinetics of all available
species; and
(v) Specification of dose steps depending on non-clinical data
(toxicity or effect).
Grounds for non-acceptance: Reasons for the provision of
GNAs issued by the BfArM are categorized in Table 1. In general,
BfArM sees key aspects of the study design as including choice
of study population, giving due consideration of aspects such as
subject age, and the description of what defines a healthy subject.
They rarely issue objections relating to number of subjects
for study, interval between dosing and dose transition. Most
common requested changes include clarification of stopping
TABLE 1 | Categorical reasons for the provision of GNAs issued by the BfArM.
Very rare objections Regular objections Critical assessments
First/starting dose Dose escalation increments Inclusion criteria (who is a healthy subject) Transition to next dose increment/cohort/next study
part requires a substantial amendment;
pharmacokinetic/pharmacodynamic to be analyzed
before proceeding
Maximum dose/exposure Dosing justification insufficient Pharmacokinetic/pharmacodynamic half-life of the
investigational medicinal products and therefore
washout times if the same subjects are participating
in multiple cohorts/accumulation for multiple dosing
parts
Maximal duration of treatment Missing sentinel approach Also for early phase trials with ‘well-known
substances’ consideration of the ‘safety factor’
Route and rate/frequency of administrations Safety (and/or effect) parameters to monitor and intensity of
monitoring (e.g., ECG, further laboratory parameter,
pregnancy test)
Number of subjects included in study cohorts Implementation of stopping criteria inappropriate
ECG, Electrocardiogram.
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criteria, missing sentinel approach, dosing justification and
inclusion criteria (Breithaupt-Groegler et al., 2017).
Centrale Commissie Mensgebonden
Onderzoek, Netherlands
Table 2 provides a summary of the essential changes
in the revised EMA FIH guideline previously noted by
Joop van Gerven, Chairman of the Central Committee
on Research Involving Human Subjects (CCMO,
Netherlands) (Bonelli and Van Gerven, 2018) and discussed
during the meeting.
Joop van Gerven highlighted how it is important to provide a
thorough description of the pharmacology and the mechanism
of action (MoA) of investigational medicinal products (IMPs)
within the protocol. He noted that insufficient emphasis is
currently being placed on collecting data that can define the
MoA of new agents. Sponsors also seem to put less effort
into researching, understanding and reporting the secondary
pharmacology characteristics. Equally, issues surrounding
pharmacokinetic and pharmacodynamic monitoring appear
to be limiting the amount of information emerging from
non-clinical pharmacology studies. And yet, most clinical
pharmacologists working for regulatory agencies are interested
in receiving as much of this type of information as possible.
Not only does such data help Sponsors make predictions of
possible ‘off target’ effects and their consequences, it also helps
investigators and regulators understand what is happening
or happened if the drug doesn’t work or if things go wrong
(Van Gerven and Cohen, 2018).
The CCMO has seen a philosophical change in its approach
to FIH clinical trials. Beyond the emphasis on pharmacology
and MoA, it is placing greater emphasis on the protocol
itself, requiring sponsors to provide justification for various
strategies, providing predefined expectations and stopping rules
as well as defining responsibilities. Effectively, this translates
into the adoption of a ‘totality of evidence’ approach to
achieving study approval that is based on integration of emerging
data. Much of the decision process after submission of a
protocol is devoted to clarification of these issues during
questions and answers.
Summarizing the experience of FIH submissions in
Netherlands, Joop van Gerven noted that, thus far, very few
studies have been rejected by CCMO since the introduction of
the revised guideline in 2017. However, clarifications and/or
modifications related to the above were often required before
approval. Where rejections occurred, sponsors had submitted
protocols that described highly complex study designs [usually
involving legally incapacitated subjects, gene modifications
or advanced therapy medicinal products (ATMPs)] but had
provided what was considered to be insufficient data to justify
their proposed clinical investigations. There were no major
changes in the number of submissions between 2013 and 2017,
consisting of about 130 Phase I trials per year; rejections making
around 2 – 5 trials. About 25% of rejections in these ‘complicated’
studies were as a consequence of the sponsor failing to establish
totality of evidence or insufficient clinical pharmacological or
mechanistic explanation.
Agence Nationale de Sécurité du
Médicament et des Produits de
Santé, France
Marc Martin, Deputy Director at the Agence Nationale de
Sécurité du Médicament et des Produits de Santé (ANSM,
France), opened his presentation by noting that he could not
discuss technical issues from the point of view of an assessor.
His unit was created to provide the expertise needed to assess
applications to conduct early phase clinical trials; this does not
include trials with cell or genetic therapies, organs, tissues or cells,
vaccines or medical devices. The agency has assessed around 90
submissions and 300 protocol amendments in the first 6 months
of 2018. Statistics indicate that the agency provides decisions on
submissions within 71 – 80 days in 2017, with intermediate letter
sent to sponsors within 70 days (on average). Since May 2018,
these delays have been reduced to around 32 days for delivery of
intermediate letters and 41 days for decisions, following process
optimization. The objective remains to reduce the time further.
The agency is committed to improving the authorization
process and facilitating access to innovation for patients. Two
fast-track evaluation processes for the early phase trials in
patients and for the trials involving a drug that has already
TABLE 2 | A summary of the essential changes in the revised EMA FIH guideline.
More emphasis on pharmacology
and action mechanism
More emphasis on protocol
arrangements
More emphasis on ‘totality of evidence’
MABEL, pharmacokinetic,
pharmacodynamic,
PAD, ATD (no MTD)










Structured IB assessment (ib-derisk.org) (European
Medicines Agency Pre-authorisation Evaluation of
Medicines for Human Use, 2005)
Translational models, Pharmacokinetic/pharmacodynamic
Decisions based on integration of emerging data
MABEL, minimal anticipated biological effect level; PAD, pharmacologically active dose; ATD, anticipated therapeutic dose; MTD, maximal tolerated dose.
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been evaluated by the agency have also been initiated by
ANSM. Issues that frequently arise from the assessment of
the CTA include poorly defined stopping rules, failure to
include a sequential approach to inclusion of patient subjects
and insufficient information on the pharmacokinetic profiles
of IMPs. Submissions also frequently fail to provide sufficient
opportunity for data review prior to inter-cohort switch during
the trial and where decisions are made they often rely simply on
pharmacokinetic data to make decisions on dose escalation.
The agency often requests that sponsors incorporate a Data
and Safety Monitoring Board (DSMB) into their study plans.
Currently, the EMAs 2006 guideline on the inclusion of data
monitoring committees is subject to interpretation and sponsors
often request clarification of the agency’s requirements for
inclusion of a DSMB (European Medicines Agency Science
Medicines Health, 2019). Pharmacovigilance issues also arise
frequently, such as there being no formal plan for communication
between participants, sponsors and investigators for serious
adverse events, Suspected Unexpected Serious Adverse Reactions
(SUSARs) or other emerging safety concerns. The consequence
seems to be a delay in the period between such episodes and
formal notification.
Státní ústav pro kontrolu léčiv, Czechia
Ondřej Palán, from SUKL, the Czech Republic’s State Institute for
Drug Control, reviewed historical data on requests submitted to
the agency to conduct clinical trials from 2017. Of 628 requests,
most studies were not conducted in the Czech republic alone
and included requests for scientific advice. Of this total, 5% were
for Phase I and 27% were Phase II studies. Critical inadequacies
frequently noted during approval review included:
1. Insufficient justification for the doses selected for study;
2. Unclear or undefined age limits;
3. Inappropriately short follow up times; and
4. Having an inadequate number of visits and related quality
of examinations.
Concerns were also expressed over the ready ‘availability’
of emergency units that are occasionally not close enough to
the study setting.
The revised guideline also emphasizes the importance of
non-clinical data from at least two relevant animal species. For
modern bioactive compounds, however, it can be difficult to
gather relevant data and there may be no acceptable models that
can provide appropriate data. Integrated protocols remain a big
challenge for regulators who need to ensure that decision points
are managed with adequate levels of care.
The Czech agency continues to adopt a risk-based approach,
addressing each new submission on a case-by-case approach,
especially in the circumstance of adaptive design studies.
Federal Agency for Medicines and Health
Products, Belgium
Sonja Beken from the Federal Agency for Medicines and Health
Products (FAMHP, Belgium) introduced the attendees to the
process of trial approval in Belgium, where in principle, the
agency reviews non-clinical/preclinical data (i.e., Investigators
Brochure) and quality data of the IMP included in the
submission. Separately from the review by the FAMHP, an ethics
committee reviews the clinical data and ethical aspects including
informed consent forms of each new application. However, this
pathway will change slightly with the implementation of the
revised FIH guideline, when everything will come under the
management of the agency. The main change is the fact that
a central body will decide which independent ethics committee
(IEC) will review the submission in order to provide further
guarantees of the independence of the IEC. The new process
is currently being tested. Up till now, about 30 pilot trials of
Phase I to IV have been performed according to the new process,
sharing the responsibility for clinical trial authorization between
the competent authority and the IEC.
The aim of FAMHP is to maintain short turnaround times for
study approval, particularly for Phase I trials, providing responses
in approximately 15 days. In 2017, there were over 500 new
applications for clinical trials and nearly 1,500 trials were run in
Belgium in 2016.
Review of the previous clinical trial submission data for
Belgium indicates that the reasons for rejections were similar
to those reported here by other agencies. These include failure
to provide appropriate justification or relevant information to
support the highest doses or not conducting non-clinical studies
in relevant animal species. Interestingly, some rejections occurred
after sponsors had asked the agency for advice but then failed to
incorporate the information and direction provided.
For the Belgium authority, Dr. Beken reported that the FIH
guideline would not change the approach to working of the
FAMHP agency and the way it looks into non-clinical and clinical
data. The agency is guided by a scientific risk-based approach.
Most GNAs issued by FAMHP are administrative in nature, with
only a handful being due to scientific issues such as:
(i) Missing data;
(ii) Ill-defined proof of concept;
(iii) Lacking of relevance of the animal species;
(iv) Insufficient non-clinical pharmacology and toxicology
data to predict clinical data with adequate confidence;
(v) Absence of a defined maximum dose with justification;
(vi) Inadequate amount of safety monitoring;
(vii) Inappropriate dosing schedule as a function of the IMPs
PK profile; and/or
(viii) Use of concomitant medication.
When performing integrated protocols, sometimes
conditional approval is possible, i.e., the single ascending dose
(SAD) part of a trial may start but the authority require more
data before the start of the MAD is permitted. A clinical trial
application may also be rejected in cases where prior scientific
advice given by EMA or at a national level has not been followed
by the sponsor with no adequate reasoning being provided.
Discussion on Conditional Approval
The audience discussed aspects of conditional approval.
A German delegate expressed the opinion, that in case of a
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conditional approval this would be more likely for integrated
protocols in Germany than in other countries. According
to Joop van Gerven conditional approval is impossible from
the legal point of view, however, the authority may ask for
additional data while the study proceeds. As there are differences
between European countries, Stefano Ponzano suggested that
specific examples could be discussed at the CTFG Meetings
to address different approaches across the European agencies.
A training curriculum that focuses on FIH trials is currently
being developed by the EMA.
DELEGATE DISCUSSION, QUESTIONS,
AND OPINIONS
Sentinel Dosing/Staggering of Subjects
Within a Multiple-Ascending Dose
(MAD) Trial
The sentinel dosing approach was discussed in detail by the
audience. Uncertainties exist in the interpretation of the timing
of sentinel groups prevail regarding MAD trials. The following
questions were raised:
1. Is a sentinel group required for each dose step in a MAD or
only for the first group?
2. How long after dosing of the sentinel subjects should the
subsequent subjects start?
3. Is this depending on operational feasibility or on PK
characteristics of the IMP?
Attendees reported divergent approaches. An overview on the
use of sentinel subjects in a MAD setting is summarized in Table 3
and based on answers given by the online tool sli.do.
The clinical practice of attendees varies between inclusion of
sentinel subjects in each cohort (SAD, MAD) or not at all in
MAD trials. In general, the audience felt that sentinel dosing
in MAD studies is not needed if SAD dose levels covered the
MAD levels, but is needed if dose escalation beyond SAD dose
levels is intended.
Attendees considered the inclusion of sentinel subjects in each
new cohort in the MAD part to be challenging. They preferred
a ‘risk-based’ over a ‘checklist’ approach. Further clarification is
required on how to define sentinel dosing:
(i) One subject on active medication and one subject
on placebo?
(ii) Split a cohort into several groups to reduce the risk (i.e.,
staggered dosing)?
As a general rule, not all subjects within a cohort should be
dosed on the same day. Important safety issues in a MAD trial
may occur when steady state has been reached and in case of
non-linear pharmacokinetics.
Regulators expressed support for an approach that uses two
front-runners (one subject on active medication and one subject
on placebo). Depending on the pharmacokinetic half-life of the
IMP, the sentinel subjects should be dosed at least 24 – 48 h before
the rest of the cohort. Regulators emphasized that according
to the revised guideline, omission of sentinel dosing requires
justification: ‘Why do people feel there is no risk?’
There was also the question whether the IEC has to give an
approval for each dose escalation step in a SAD or a MAD trial if
the steps are within the range defined in the trial protocol? Kirsty
Wydenbach explained how, where the authorities have approved
the protocol, no interim report or amendments are required.
Attendees asked how far the dose escalation may proceed in an
adaptive design trial and whether this would only depend on
safety data? Kirsty Wydenbach commented that it depends on
the dose escalation steps and details specified in the protocol. An
attendee reported that Belgian IECs for some FIH trials requested
safety reports on individual dose step to remain informed about
the decisions on further dose escalation, without necessarily
requiring approval (i.e., notification).
The audience felt that this point highlighted differences
between European agencies and that the decision procedure
requires further harmonization across Europe. Trust should be
built between authorities and sponsors as well as investigators. It
was proposed that a sponsor personal liability concept (equaling
the personal liability defined in the Qualified Person concept)
might help to increase trust between stakeholders.
Maximum Exposure/Supra-Therapeutic
Doses
The next point of discussion addressed why - in contrast to
what was the common procedure about a decade ago – current
practices preclude the determination of the MTD in a FIH trial
in healthy subjects. Nevertheless, a supra-therapeutic dose needs
to be defined. Safety margins are required regarding therapeutic
doses in the transition from healthy subjects to patients. A supra-
therapeutic dose is also required for certain types of safety trials
(e.g., thorough QT trial). Accordingly, predefining the adequate
exposure cap for a FIH trial needs to be carefully considered.
Regulators commented that the MTD is by definition a dose
below a toxic dose and thus can only be determined by the
observation of a toxic dose level, which is no longer considered
acceptable in healthy subjects. A supra-therapeutic dose can be
TABLE 3 | An overview on the use of sentinel subjects in a MAD setting.
Question Respondents Yes % No % It depends
Who did ever implement a sentinel dose group in a MAD part of a trial? N = 63 57 43 n.a.
Do you need a sentinel approach in MAD trials if these doses have
already been studied in a SAD trial?
N = 68 19 16 65%
Do you need a sentinel approach in MAD trials if they contain a dose
escalation beyond the prior SAD trial?
N = 46 74 2 24%
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administered to healthy volunteers if an appropriate rationale is
provided and the selected dose is clearly below toxic levels. It is
imperative to avoid the MTD in healthy subjects.
Yet, often there seems to be a misunderstanding regarding
the notion of ‘supra-therapeutic’ dose, this does not need
to be, for example, a 10-fold higher dose than the intended
therapeutic dose. Recent experience shows a trend for
lower maximum doses in FIH trials in healthy subjects.
Pharmacokinetic/pharmacodynamic guidance, including the
influence of the disease or other patient characteristics and
applying a risk-based approach may help to identify the
adequate exposure cap.
It is imperative to define maximum exposure in the protocol.
Regulators stated they would expect an early phase trial to
establish a well-defined top dose in order to ascertain the
therapeutic window.
Dose Escalation Above the NOAEL
Another important question discussed by regulators and
audience was whether – in an ascending dose design – an
exposure above NOAEL would be acceptable.
Some delegates felt this cannot be answered in general terms
but rather requires a risk-based approach, involving a discussion
between sponsor and investigator on the IMP and the nature and
severity of non-clinical findings as well as the mechanism and
clinical ‘monitorability’ of safety/tolerability. The trial protocol
should clearly define whether mean exposure of an entire dose
group or exposure of an individual subject must not be in
excess of NOAEL, precluding further dose escalation. Stefano
Ponzano pointed out that the FIH guideline in this context
indicates individual exposure and Joop van Gerven stated that
NOAEL is defined on the basis of individual animals. This view
was supported by a delegate from the audience, emphasizing
that individual exposure should be checked as the number of
subjects in a FIH trial is limited. Another delegate disagreed,
mentioning that individual animals are taken into account to
evaluate toxicology findings, but pharmacokinetic information is
typically associated with mean data. To allow a comprehensive
understanding of NOAEL data, the individual animal toxicology
findings should be related to the individual pharmacokinetic data.
The audience felt that – based on all available information – the
Principal Investigator needs to be convinced that progression to
a higher dose step is safe.
Relevance of Pharmacodynamic Assays
in Non-clinical and Clinical Development
The discussion continued regarding the relevance of
pharmacodynamic assays to be used for dose escalation
decisions and definition of stopping criteria. What if the
appropriate biomarkers are not known or not yet available
in FIH trials? In response, Joop van Gerven stated that a
good pharmacological rationale is the foundation/pillar for
the development of a new compound. Therefore, appropriate
biomarker/pharmacodynamic measures for the activity of the
drug need to be developed and used in non-clinical and clinical
studies. Delegates agreed that based on their own experience,
the development of biomarkers is time-consuming, expensive,
and not always successful. This is particularly the case for
disease biomarkers, but it may also be difficult to find reliable
pharmacodynamics markers. Sonja Beken insisted, if dosing is
not based on pharmacological considerations, the results of drug
development will not be stringent. Joop van Gerven emphasized
the importance to characterize the pharmacological activity
of a drug. Especially in early phase trials, pharmacodynamic
data are very informative and helpful for decision-making, and
they reduce the chance of drug development failures. Stefano
Ponzano agreed every effort must be made to demonstrate the
pharmacological effects, even if no appropriate biomarkers
are available. Kirsty Wydenbach stated the analysis of the
pharmacodynamic/pharmacokinetic interaction could also
contribute to safety assessments. Some delegates, however, saw
limitations to PD-marker guided decisions during conduct of
the study as these markers often are only analyzed after the trial
is completed. Joop van Gerven responded that such limitations
often require a more cautious approach, especially for new
targets or high-risk compounds.
The audience questioned the regulators whether, in cases
where non-clinical studies failed to establish the expected
pharmacological characteristics of a new compound, it
would be justified to increase the dose in a FIH setting and
look at safety and pharmacokinetics only? Joop van Gerven
suggested that if a marker could not be found, dose escalation
may be guided by solely by safety and pharmacokinetics,
provided that particular emphasis is placed on predictions
of target concentrations based on human predictions of
the pharmacologically active concentration range, using
good preclinical pharmacodynamic/pharmacokinetic-models
(preferably incorporating efficacy and safety) and, if possible,
include drug measurements close to the target site (e.g.,
in the cerebrospinal fluid for drugs acting in the central
nervous system).
HARMONIZATION BETWEEN
COUNTRIES AND STRATEGIES OF THE
INDUSTRY
At the completion of the forum, attendees were asked about their
current experience with competent authorities and about their
BOX 1 | Applicant differences between European countries. Question:
According to your experience, do regulators apply the new guidance with the
same approach across Europe?
Sixty answers resulted in 12% Yes and 88% No
Question: Do applicants go shopping for the country/agency with the
perceived lowest hurdles?
Sixty six answers resulted in 89% Yes and 11% No
Question: What do applicants shop for?




Quality of advice: 61%
Time-saving 94%
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strategies in facing any perceived regulatory challenge. The online
tool sli.do was used, answers were provided anonymously.
The data on harmonization between countries suggest the
following conclusions:
Applicants experience remarkable differences between
European countries. A large proportion of applicants go
‘shopping’ for the agency with the perceived lowest hurdles
and the most frequent reason to do this is to save time (Box 1).
In response, regulators emphasized that current training
initiatives are organized by EMA. Regular CTFG meetings are
held to ensure that major aspects of evaluation would be the
same, even if some standards differ across Europe. Regulators
also expect that with application of the new EU clinical trial
regulation harmonization across Europe will increase.
CONCLUSION
In closing the meeting it was generally agreed that the
necessary changes encompassed by new guidelines included
both constructive and disruptive aspects. Sixty-nine delegates
took part in the final vote on whether the new FIH
guideline is disruptive or constructive: 51% stated it was
both constructive and disruptive, 48% decided on constructive,
none on disruptive and 1% were still undecided. It was
generally accepted that stakeholders need to continue in a
process of stakeholder engagement and discussion, particularly
on critical safety issues. Such an approach allows partners
to adopt a proactive approach to sharing best practice. For
example, attendees agreed that a ‘Question and Answer’
document harmonized between the European agencies is
required for the sentinel approach and for the selection of
supratherapeutic doses.
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